Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial

Journal of Cystic Fibrosis

Volumn 12, Issue 2, 2013, Pages 147-153

  Anstead, Michael ^a   Heltshe, Sonya L ^b   Khan, Umer ^c   Barbieri, Joseph T ^d   Langkamp, Markus ^e   Döring, Gerd ^f   Dharia, Shimoni ^g   Gibson, Ronald L ^b   Treggiari, Miriam M ^h   Lymp, James ^c   Rosenfeld, Margaret ^b   Ramsey, Bonnie ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e Mediagnost   (Germany)

^f UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^g CHILDREN S HOSPITAL OF WISCONSIN   (United States)

^h SEATTLE CHILDREN S HOSPITAL   (United States)

Author keywords

EPIC; Infection; Pseudomonas; Serology; Treatment

Indexed keywords

ALKALINE PROTEINASE; EXOTOXIN; EXOTOXIN A; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT;

ARTICLE; BACTERIUM ISOLATION; DISEASE EXACERBATION; DRUG TREATMENT FAILURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; NONHUMAN; PSEUDOMONAS AERUGINOSA; RECURRENCE RISK; RECURRENT INFECTION; SEROLOGY; BLOOD; CHILD; COMPLICATION; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PROGNOSIS; PSEUDOMONAS INFECTIONS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK FACTOR;

ANTI-BACTERIAL AGENTS; BACTERIOLOGICAL TECHNIQUES; CHILD; CYSTIC FIBROSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; PROGNOSIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RECURRENCE; RISK FACTORS; SEROLOGIC TESTS;

EID: 84878014012     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2012.08.001     Document Type: Article

References (35)

1. Frederiksen B., Koch C., Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997, 23:330-335.
2. Taccetti G., Campana S., Festini F., Mascherini M., Doring G. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 2005, 26:458-461.
3. Doring G., Hoiby N. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 2004, 3:67-91.
4. Rosenfeld M., Gibson R.L., McNamara S., Emerson J., Burns J.L., Castile R., et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol 2001, 32:356-366.
5. Burns J.L., Gibson R.L., McNamara S., Yim D., Emerson J., Rosenfeld M., et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 2001, 183:444-452.
6. Saiman L., Siegel J. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Am J Infect Control 2003, 31:S1-S62.
7. Rosenfeld M., Emerson J., Accurso F., Armstrong D., Castile R., Grimwood K., et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol 1999, 28:321-328.
8. Ratjen F., Walter H., Haug M., Meisner C., Grasemann H., Doring G. Diagnostic value of serum antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis patients. Pediatr Pulmonol 2007, 42:249-255.
9. Douglas T.A., Brennan S., Berry L., Winfield K., Wainwright C.E., Grimwood K., et al. Value of serology in predicting Pseudomonas aeruginosa infection in young children with cystic fibrosis. Thorax 2010, 65:985-990.
10. Kappler M., Kraxner A., Reinhardt D., Ganster B., Griese M., Lang T. Diagnostic and prognostic value of serum antibodies against Pseudomonas aeruginosa in cystic fibrosis. Thorax 2006, 61:684-688.
11. Tramper-Stranders G.A., van der Ent C.K., Slieker M.G., Terheggen-Lagro S.W., Teding van Berkhout F., Kimpen J.L., et al. Diagnostic value of serological tests against Pseudomonas aeruginosa in a large cystic fibrosis population. Thorax 2006, 61:689-693.
12. Farrell P.M., Govan J.R. Pseudomonas serology: confusion, controversy, and challenges. Thorax 2006, 61:645-647.
13. Ratjen F., Doring G., Nikolaizik W.H. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 2001, 358:983-984.
14. West S.E., Zeng L., Lee B., Kosorok M.R., Laxova A., Rock M., et al. Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis: early detection by serology and assessment of risk factors. J Am Med Assoc 2002, 287:2958-2967.
15. Hayes D., Farrell P.M., Li Z., West S.E. Pseudomonas aeruginosa serological analysis in young children with cystic fibrosis diagnosed through newborn screening. Pediatr Pulmonol 2010, 45:55-61.
16. Doring G., Meisner C., Stern M. A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc Natl Acad Sci U S A 2007, 104:11020-11025.
17. Corech R., Rao A., Laxova A., Moss J., Rock M.J., Li Z., et al. Early immune response to the components of the type III system of Pseudomonas aeruginosa in children with cystic fibrosis. J Clin Microbiol 2005, 43:3956-3962.
18. Milagres L.G., Castro T.L., Garcia D., Cruz A.C., Higa L., Folescu T., et al. Antibody response to Pseudomonas aeruginosa in children with cystic fibrosis. Pediatr Pulmonol 2009, 44:392-401.
19. Treggiari M.M., Retsch-Bogart G., Mayer-Hamblett N., Khan U., Kulich M., Kronmal R., et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med 2011, 165:847-856.
20. Anstead M., Lymp J., Khan U., Barbieri J., Langkamp M., Doring G., et al. Pseudomonas aeruginosa serology predicts response to treatment and re-infection inthe EPIC clinical study (abstract). Pediatr Pulmonol 2011, S34:303-304.
21. Lee T.W., Brownlee K.G., Conway S.P., Denton M., Littlewood J.M. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros 2003, 2:29-34.
22. Mayer-Hamblett N., Kronmal R.A., Gibson R.L., Rosenfeld M., Retsch-Bogart G., Treggiari M.M., et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatr Pulmonol 2012, 47:125-134.
23. Billard-Pomares T., Herwegh S., Wizla-Derambure N., Turck D., Courcol R., Husson M.O. Application of quantitative PCR to the diagnosis and monitoring of Pseudomonas aeruginosa colonization in 5-18-year-old cystic fibrosis patients. J Med Microbiol 2011, 60:157-161.
24. McCulloch E., Lucas C., Ramage G., Williams C. Improved early diagnosis of Pseudomonas aeruginosa by real-time PCR to prevent chronic colonisation in a paediatric cystic fibrosis population. J Cyst Fibros 2011, 10:21-24.
25. da Silva Filho L.V., Tateno A.F., Martins K.M., Azzuz Chernishev A.C., Garcia Dde O., Haug M., et al. The combination of PCR and serology increases the diagnosis of Pseudomonas aeruginosa colonization/infection in cystic fibrosis. Pediatr Pulmonol 2007, 42:938-944.
26. Shaw P.A., Pepe M.S., Alonzo T.A., Etzioni R. Methods for assessing improvement in specificity when a biomarker is combined with a standard screening test. Stat Biopharm Res 2009, 1:18-25.
27. Etzioni R. Statistical issues in the evaluation of screening and early detection modalities. Urol Oncol: Semin Orig Investig 2008, 26:308-315.
28. Saslow D., Solomon D., Lawson H.W., Killackey M., Kulasingam S.L., Cain J., et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012, 62:147-172.
29. Arbyn M., Ronco G., Cuzick J., Wentzensen N., Castle P.E. How to evaluate emerging technologies in cervical cancer screening?. Int J Cancer 2009, 125:2489-2496.
30. Etzioni R., Falcon S., Gann P.H., Kooperberg C.L., Penson D.F., Stampfer M.J. Prostate-specific antigen and free prostate-specific antigen in the early detection of prostate cancer: do combination tests improve detection?. Cancer Epidemiol Biomarkers Prev 2004, 13:1640-1645.
31. Etzioni R., Kooperberg C., Pepe M., Smith R., Gann P.H. Combining biomarkers to detect disease with application to prostate cancer. Biostatistics 2003, 4:523-538.
32. Doring G., Hoiby N. Longitudinal study of immune response to Pseudomonas aeruginosa antigens in cystic fibrosis. Infect Immun 1983, 42:197-201.
33. Wheeler W.B., Williams M., Matthews W.J., Colten H.R. Progression of cystic fibrosis lung disease as a function of serum immunoglobulin G levels: a 5-year longitudinal study. J Pediatr 1984, 104:695-699.
34. Brett M.M., Ghoneim A.T., Littlewood J.M. Prediction and diagnosis of early Pseudomonas aeruginosa infection in cystic fibrosis: a follow-up study. J Clin Microbiol 1988, 26:1565-1570.
35. Proesmans M., Els C., Vermeulen F., De Boeck K. Change in IgG and evolution of lung function in children with cystic fibrosis. J Cyst Fibros 2011, 10:128-131.